(:CBAY)

Mar 22, 2024 09:18 am ET
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
Mar 04, 2024 08:00 am ET
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the Marketing Authorization Application (MAA) for seladelpar, for the...
Feb 29, 2024 12:25 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Everi Holdings Inc. (NYSE – EVRI), Sterling Check Corp. (Nasdaq – S
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 28, 2024 04:45 pm ET
CymaBay Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year...
Feb 24, 2024 10:10 am ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CBAY, IONM, WISH, FREE
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CymaBay Therapeutics, Inc. (NASDAQ:...
Feb 21, 2024 04:43 pm ET
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
-  Seladelpar demonstrated normalization of liver biomarkers and significant reductions across three measures of patient-reported itch vs. placebo - 
Feb 20, 2024 04:05 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees on...
Feb 17, 2024 12:18 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, ZFOX, CBAY, WISH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Masonite International Corporation...
Feb 16, 2024 01:58 pm ET
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CymaBay Therapeutics, Inc. - CBAY
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CymaBay Therapeutics, Inc. (NasdaqGS: CBAY) to Gilead Sciences, Inc. (NasdaqGS: GILD). Under the terms of the proposed transaction, shareholders of CymaBay will receive $32.50 in cash for each share of CymaBay that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Feb 12, 2024 05:45 pm ET
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, CBAY, WISH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Diamondback Energy, Inc. (NASDAQ:...
Feb 12, 2024 03:44 pm ET
ALERT: The M&A Class Action Firm Launches Investigation of the Merger – WISH, IONM, CBAY, FANG
Juan Monteverde, founder and managing partner of Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
Feb 12, 2024 12:43 pm ET
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.  Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. 
Feb 12, 2024 11:30 am ET
INVESTIGATION ALERT: Halper Sadeh LLC Investigates FANG, WISH, CBAY
NEW YORK, Feb. 12, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 12, 2024 11:17 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CymaBay Therapeutics, Inc. (Nasdaq – CBAY), Masonite International Corporation (NYSE – DOOR), ZeroFox Holdings,
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 12, 2024 10:45 am ET
Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead
MILWAUKEE, Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY)  for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead.
Feb 12, 2024 09:35 am ET
CBAY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CymaBay Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) to Gilead Sciences, Inc. for $32.50 per share in cash is fair to CymaBay shareholders.
Feb 12, 2024 08:30 am ET
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its long-standing commitment to bringing transformational medicines to patients.
Feb 12, 2024 07:45 am ET
Jan 31, 2024 08:00 am ET
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Guggenheim...
Jan 16, 2024 04:28 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on...
Jan 02, 2024 08:00 am ET
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at...
Dec 18, 2023 04:05 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to four employees on...
Dec 15, 2023 07:00 am ET
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
- NDA is supported by data evaluating seladelpar efficacy and safety in over 500 patients - 
Nov 17, 2023 04:15 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to five employees on...
Nov 13, 2023 07:00 am ET
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®
61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on placebo (p<0.0001)
Nov 07, 2023 04:04 pm ET
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced corporate updates and financial results for the third quarter ended September...
Nov 06, 2023 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investment Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the UBS Biopharma...
Nov 01, 2023 08:00 am ET
CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that two-year safety and efficacy results of seladelpar for primary biliary...
Oct 31, 2023 04:05 pm ET
CymaBay Therapeutics to Report Third Quarter of 2023 Financial Results on Tuesday, November 7, 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday,...
Oct 23, 2023 04:05 pm ET
CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced today the presentation of findings from its post-hoc analysis of the Phase 3...
Oct 23, 2023 08:00 am ET
Seladelpar Granted Revised Breakthrough Therapy Designation for the Treatment of Primary Biliary Cholangitis Including Pruritus in Patients Without Cirrhosis or With Compensated Cirrhosis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) has revised the originally...
Oct 18, 2023 08:00 am ET
CymaBay’s RESPONSE Phase 3 Data Evaluating Seladelpar for Primary Biliary Cholangitis to be Featured in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation highlighting results from the RESPONSE...
Oct 16, 2023 04:05 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to two employees on...
Sep 21, 2023 08:00 am ET
CymaBay Initiates AFFIRM, a Phase 3b/4 Study Evaluating the Effect of Seladelpar on Clinical Outcomes in Patients with Cirrhosis due to Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced the initiation of AFFIRM, a randomized, placebo-controlled confirmatory study...
Sep 15, 2023 08:00 am ET
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Cantor Global...
Sep 14, 2023 04:57 pm ET
CymaBay Announces Closing of Upsized $258.7 Million Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the closing of its previously...
Sep 11, 2023 10:15 pm ET
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously...
Sep 11, 2023 06:00 am ET
CymaBay Announces Proposed $150 Million Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an...
Sep 06, 2023 04:05 pm ET
CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will host an investor call on Thursday,...
Aug 28, 2023 04:29 pm ET
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees...
Aug 10, 2023 04:04 pm ET
CymaBay Reports Second Quarter and Six Months Ended June 30, 2023 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today corporate updates and financial results for the second...
Aug 03, 2023 04:05 pm ET
CymaBay Therapeutics to Report Second Quarter of 2023 Financial Results on Thursday, August 10, 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio...
Jun 21, 2023 03:00 am ET
CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Additional data presented at The International Liver Congress™ 2023 show clinical risk factors for PBC disease progression present in a broader population of UDCA-treated PBC patients
Jun 07, 2023 02:00 am ET
CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023
Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression
May 15, 2023 04:04 pm ET
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing innovative therapies for liver and other chronic diseases, today announced corporate updates and financial results for the first quarter ended March 31,...
May 10, 2023 08:00 am ET
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
May 09, 2023 08:00 am ET
CymaBay Names Harish Shantharam Chief Financial Officer
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that seasoned biopharma executive Harish Shantharam,...
Apr 21, 2023 08:00 am ET
CymaBay Therapeutics Announces Publication of Results From the ENHANCE, Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3...
Apr 17, 2023 08:00 am ET
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright...
Mar 16, 2023 04:04 pm ET
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year...
Mar 09, 2023 04:05 pm ET
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Mar 01, 2023 08:00 am ET
CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer...
Feb 06, 2023 08:00 am ET
CymaBay Therapeutics to Present at the SVB Securities Global Biopharma Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities...
Jan 30, 2023 08:00 am ET
CymaBay Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously...
Jan 24, 2023 07:31 am ET
Thinking about buying stock in Grom Social Enterprises, Intelligent Bio Solutions, Polypid, CymaBay Therapeutics, or Draganfly?
NEW YORK, Jan. 24, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GROM, INBS, PYPD, CBAY, and DPRO.
Jan 24, 2023 07:00 am ET
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced...
Jan 23, 2023 04:11 pm ET
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public...
Jan 08, 2023 12:00 pm ET
CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (“CymaBay” or the “Company”) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (“Kaken”) for the development and commercialization in Japan...
Nov 14, 2022 04:06 pm ET
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2022 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the third...
Nov 07, 2022 04:05 pm ET
CymaBay Therapeutics to Report Third Quarter of 2022 Financial Results on Monday, November 14, 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Nov 04, 2022 08:00 am ET
CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis at The Liver Meeting® 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced encouraging seladelpar data in patients...
Nov 03, 2022 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investment Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Credit Suisse...
Nov 01, 2022 08:01 am ET
CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Charles McWherter as President...
Oct 03, 2022 08:00 am ET
CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that three abstracts related to its...
Sep 14, 2022 08:00 am ET
CymaBay Therapeutics Hosting Virtual Analyst Day on September 22
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will host a virtual analyst day on...
Sep 06, 2022 08:02 am ET
CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright...
Aug 24, 2022 08:00 am ET
CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a mini symposium on...
Aug 11, 2022 04:05 pm ET
CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second...
Aug 04, 2022 04:05 pm ET
CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Aug 01, 2022 08:00 am ET
CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the completion of enrollment for RESPONSE, a global...
Jun 22, 2022 08:00 am ET
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients with primary...
Jun 08, 2022 08:00 am ET
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be...
May 23, 2022 08:00 am ET
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of clinical...
May 12, 2022 04:06 pm ET
CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the first...
May 11, 2022 08:00 am ET
CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple Phase 2 and Phase 3 study...
May 05, 2022 04:01 pm ET
CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Apr 04, 2022 08:00 am ET
CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the Phase 2, 52-week...
Mar 17, 2022 04:25 pm ET
CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of...
Mar 17, 2022 04:06 pm ET
CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth...
Mar 10, 2022 04:05 pm ET
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Feb 10, 2022 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in two virtual...
Nov 18, 2021 08:00 am ET
CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Nov 17, 2021 04:33 pm ET
CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Nov 15, 2021 08:00 am ET
CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results of analyses from two clinical...
Nov 11, 2021 08:00 am ET
CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a Key Opinion Leader (KOL) webinar on...
Nov 10, 2021 04:06 pm ET
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the third...
Nov 04, 2021 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Nov 03, 2021 04:05 pm ET
CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Oct 01, 2021 08:00 am ET
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple presentations of results...
Aug 30, 2021 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Aug 12, 2021 04:06 pm ET
CymaBay Reports Second Quarter and Six Months Ended June 30, 2021 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second...
Aug 05, 2021 04:01 pm ET
CymaBay Therapeutics to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Aug 02, 2021 08:00 am ET
CymaBay Announces $100 Million Non-Dilutive Financing with Abingworth
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced a $100 million non-dilutive financing transaction with...
Jun 21, 2021 08:00 am ET
CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced positive data from its previously completed Phase 2...
Jun 14, 2021 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Jun 09, 2021 08:00 am ET
CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be...
May 18, 2021 08:00 am ET
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced  the grant of an inducement award to Dennis Kim, MD in...
May 13, 2021 04:06 pm ET
CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the first...
May 13, 2021 08:00 am ET
CymaBay Welcomes Dennis D. Kim, MD, MBA as Chief Medical Officer
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that medical and clinical leader Dennis D. Kim, MD,...
May 11, 2021 08:00 am ET
CymaBay Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of an inducement award to Lewis Stuart in...
May 10, 2021 08:00 am ET
CymaBay Names Lewis Stuart Chief Commercial Officer
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that seasoned biopharma executive Lewis Stuart has...
May 06, 2021 08:00 am ET
CymaBay Therapeutics to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Apr 05, 2021 08:00 am ET
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of biopharma veteran Thomas Wiggans and...
Mar 25, 2021 04:10 pm ET
CymaBay Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth...
Mar 12, 2021 08:00 am ET
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 25, 2021
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Mar 11, 2021 08:00 am ET
CymaBay Therapeutics to Present at the 2021 NASH-TAG Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that two seladelpar presentations will be delivered...
Feb 24, 2021 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Feb 10, 2021 08:00 am ET
CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leerink...
Nov 16, 2020 04:01 pm ET
CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 202
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced an oral late-breaking presentation of the...
Nov 11, 2020 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Nov 05, 2020 04:05 pm ET
CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the third...
Nov 05, 2020 08:00 am ET
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced it will provide its proprietary investigational GPR119...
Nov 02, 2020 08:00 am ET
CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that a late-breaking presentation...
Oct 30, 2020 04:31 pm ET
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Oct 01, 2020 08:00 am ET
CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that data from a Phase 2 study of...
Sep 22, 2020 07:00 am ET
Milestone Pharmaceuticals Strengthens Board of Directors with Two New Appointments
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Lisa Giles and Robert Wills to its Board of Directors, effective October 1, 2020. Ms. Giles will serve as a member of the Audit Committee of the Board and Dr. Wills will serve as a member of the Nominating & Corporate Governance Committee of the Board. 
Sep 03, 2020 04:05 pm ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three virtual...
Aug 27, 2020 08:00 am ET
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced final results from a previously completed...
Aug 20, 2020 08:00 am ET
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that two seladelpar presentations will be...
Aug 10, 2020 04:01 pm ET
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the second...
Aug 03, 2020 04:01 pm ET
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Aug 03, 2020 09:31 am ET
Thinking about buying stock in CymaBay Therapeutics, Trevena Inc, Co-Diagnostics, Plug Power, or Aurora Cannabis?
NEW YORK, Aug. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CBAY, TRVN, CODX, PLUG, and ACB.
Aug 03, 2020 07:00 am ET
CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced positive topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of primary biliary cholangitis...
Jul 23, 2020 10:35 am ET
Thinking about buying stock in Milestone Pharmaceuticals, Advanced Micro Devices, CymaBay Therapeutics, Pfizer Inc, or AT&T?
NEW YORK, July 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MIST, AMD, CBAY, PFE, and T.
Jul 23, 2020 08:00 am ET
FDA Lifts All Clinical Holds on Seladelpar
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that the Food and Drug Administration (FDA) lifted...
Jun 19, 2020 08:00 am ET
CymaBay Therapeutics Presents Data at Digestive Disease Week 2020 Online Education
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously completed...
Jun 05, 2020 05:00 pm ET
Notice of Change of Location of Annual Meeting of Stockholders to be Held on June 23, 2020
CymaBay Therapeutics, Inc. (Nasdaq: CBAY),  a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that, due to public health and safety concerns related...
May 13, 2020 09:31 am ET
Thinking about trading stocks or options in Livongo Health, JD.Com, CymaBay Therapeutics, GrubHub, or Ford?
NEW YORK, May 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LVGO, JD, CBAY, GRUB, and F.
May 11, 2020 04:01 pm ET
CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the first...
May 04, 2020 04:43 pm ET
CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Mar 13, 2020 05:29 pm ET
CymaBay Therapeutics Comments on Engine Capital Director Nominations
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) (the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today confirmed that Engine Capital Management (“Engine”) has nominated three candidates to stand for election to the Company’s Board of Directors (the “Board”) at the 2020 Annual Meeting. Shareholders are not required to take any action at this time. CymaBay issued the following statement:
Mar 12, 2020 04:01 pm ET
CymaBay Reports Fourth Quarter and Fiscal Year End 2019 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth...
Mar 09, 2020 07:51 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Investigation Into Possible Securities Fraud Ongoing
Hagens Berman urges investors in CymaBay Therapeutics, Inc. (NASDAQ: CBAY) who have suffered significant losses to submit their losses now.  The firm is investigating possible securities law violations, and certain investors may have valuable...
Mar 09, 2020 10:57 am ET
ROSEN, A LEADING LAW FIRM, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAY
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of CymaBay Therapeutics, Inc. (NASDAQ: CBAY), resulting from allegations that CymaBay may have issued materially...
Mar 05, 2020 04:01 pm ET
CymaBay Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, March 12
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Mar 04, 2020 06:09 pm ET
CYMABAY ALERT: Bragar Eagel & Squire, P.C. Is Investigating CymaBay Therapeutics, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY) on behalf of CymaBay stockholders. Our investigation concerns whether CymaBay has violated the federal securities laws and/or engaged in other unlawful business practices.
Mar 03, 2020 03:12 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CymaBay Therapeutics, Inc. (“CymaBay” or “the Company”) (NASDAQ:
Mar 03, 2020 12:27 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CymaBay Therapeutics (CBAY) Investors Who Have Suffered Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud
Hagens Berman urges investors in CymaBay Therapeutics, Inc. (NASDAQ: CBAY) who have suffered significant losses to submit their losses now.  The firm is investigating possible securities law violations, and certain investors may have valuable...
Mar 02, 2020 06:07 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against CymaBay Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CymaBay Therapeutics, Inc. (“CymaBay” or “the Company”) (NASDAQ:
Mar 02, 2020 04:15 pm ET
EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against CymaBay Therapeutics, Inc. – CBAY
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of CymaBay Therapeutics, Inc. (NASDAQ: CBAY), resulting from allegations that CymaBay may have issued materially misleading business information to the investing public.
Mar 02, 2020 08:09 am ET
CymaBay Therapeutics Investigated for Possible Securities Fraud by Block & Leviton
National securities litigation firm Block & Leviton (www.blockesq.com) is investigating potential claims against CymaBay Therapeutics, Inc. (NASDAQ: CBAY) and certain of its officers for securities fraud.  Investors who have suffered losses are...
Jan 29, 2020 04:15 pm ET
CymaBay Publishes Shareholder Letter
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the publication of a Letter to Shareholders. In this...
Nov 25, 2019 08:00 am ET
CymaBay Therapeutics Halts Clinical Development of Seladelpar
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that the company was terminating its Phase 2b study of...
Nov 14, 2019 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Nov 05, 2019 04:10 pm ET
CymaBay Reports Third Quarter 2019 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the...
Nov 04, 2019 08:00 am ET
CymaBay Therapeutics Reaches Target Enrollment in the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with a high unmet medical need, today...
Oct 28, 2019 08:00 am ET
CymaBay Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 5
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Oct 14, 2019 08:00 am ET
CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Oct 01, 2019 04:05 pm ET
CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2019
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The Liver Meeting® hosted by the American...
Sep 30, 2019 08:00 am ET
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Sep 17, 2019 04:30 pm ET
CymaBay Therapeutics Announces Departure of Chief Medical Officer
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that...
Sep 03, 2019 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Aug 07, 2019 04:10 pm ET
CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the...
Aug 05, 2019 08:00 am ET
CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced the addition of Ms. Janet Dorling as Chief...
Jul 31, 2019 04:23 pm ET
CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Jun 18, 2019 08:00 am ET
CymaBay Therapeutics Announces IND to Commence a Clinical Study of Seladelpar to Treat Primary Sclerosing Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced FDA clearance of the company’s...
Jun 17, 2019 08:00 am ET
CymaBay Therapeutics to Participate in the Raymond James Life Sciences and MedTech Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that Sujal Shah, President and Chief...
Jun 11, 2019 07:00 am ET
CymaBay Therapeutics Reports Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced 12-week topline results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis (NASH). Seladelpar is a...
May 20, 2019 04:01 pm ET
CymaBay Therapeutics Presents Data in Patients with Primary Biliary Cholangitis at DDW 2019
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced results related to its seladelpar clinical...
May 08, 2019 04:05 pm ET
CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the...
May 08, 2019 08:00 am ET
CymaBay Therapeutics Announces Multiple Presentations at DDW 2019
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple abstracts related to its seladelpar clinical development program for the treatment of primary biliary cholangitis (PBC) will be presented in poster sessions at Digestive...
Apr 30, 2019 08:00 am ET
CymaBay Therapeutics to Report First Quarter 2019 Financial Results on Wednesday, May 8
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Apr 12, 2019 08:00 am ET
CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced positive results from its Phase 2 study of...
Mar 27, 2019 08:00 am ET
CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that multiple seladelpar presentations will be delivered during The International Liver CongressTM of the European Association for the Study of Liver (EASL) in Vienna, Austria from April...
Mar 25, 2019 07:00 am ET
Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Louisiana-Pacific Corporation (NYSE:LPX), The Michaels Companies, Inc....
Mar 12, 2019 08:00 am ET
CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Mar 11, 2019 04:05 pm ET
CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet need, today announced the...
Mar 06, 2019 08:00 am ET
CymaBay Announces Pricing of Public Offering of Common Stock
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Mar 05, 2019 04:01 pm ET
CymaBay Announces Proposed Public Offering of Common Stock
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today...
Feb 28, 2019 04:05 pm ET
CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter...
Feb 22, 2019 07:40 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Ec
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Apple Inc. (NASDAQ:AAPL), United Continental Holdings, Inc. (NASDAQ:UAL),...
Feb 21, 2019 08:00 am ET
CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Feb 20, 2019 08:00 am ET
CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in a fireside chat at...
Feb 19, 2019 08:00 am ET
CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced the early completion of enrollment in a Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis (NASH). The company expects to...
Feb 15, 2019 08:00 am ET
CymaBay Therapeutics Announces Seladelpar Granted Breakthrough Therapy Designation by the FDA for the Treatment of Primary Biliary Cholangitis
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for seladelpar for the treatment of early stage primary biliary cholangitis (PBC) in...
Jan 02, 2019 08:00 am ET
CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that Sujal Shah, President and Chief Executive Officer,...
Nov 27, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ForeScout Technologies, Inc. (NASDAQ:FSCT), GNC Holdings, Inc....
Nov 20, 2018 08:00 am ET
CymaBay Therapeutics to Participate in Upcoming Investor Conferences
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in three upcoming...
Nov 13, 2018 08:00 am ET
CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) presented data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). Presentations were delivered during two late-breaking presentations yesterday at The Liver...
Nov 06, 2018 04:10 pm ET
CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter...
Oct 30, 2018 04:05 pm ET
CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Oct 30, 2018 08:00 am ET
CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that the company has initiated the seladelpar Phase 3 registration study for the treatment of Primary Biliary Cholangitis (PBC). The study is a 52-week, placEbo-coNtrolled, randomized,...
Oct 10, 2018 07:40 am ET
Report: Developing Opportunities within Brunswick, Pebblebrook Hotel Trust, Avaya, Braskem S.A, CymaBay Therapeutics, and The Blackstone Group — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Brunswick Corporation (NYSE:BC), Pebblebrook Hotel Trust (NYSE:PEB), Avaya...
Oct 03, 2018 09:00 am ET
CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that two late-breaking presentations describing new long-term data from its ongoing Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC) will be featured on...
Sep 24, 2018 08:00 am ET
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor...
Aug 14, 2018 08:00 am ET
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September
CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor...
Aug 09, 2018 04:01 pm ET
CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter...
Aug 02, 2018 08:00 am ET
CymaBay to Report Second Quarter 2018 Financial Results on Thursday, August 9
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Aug 01, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Five Prime Therapeutics, Akorn, The Blackstone Group, Avaya, Tractor Supply, and CymaBay Therapeutics — New Research Emphasizes Econ
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Prime Therapeutics, Inc. (NASDAQ:FPRX), Akorn, Inc. (NASDAQ:AKRX),...
Jun 25, 2018 08:00 am ET
CymaBay Therapeutics Added to the Russell 3000® and Russell 2000® Indexes
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that is being added to the Russell 3000® and the Russell...
Jun 19, 2018 08:00 am ET
CymaBay Therapeutics to Host Analyst and Investor Day on June 26, 2018
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, will host an analyst and investor day on June 26, 2018 from 12:00pm to...
May 08, 2018 04:01 pm ET
CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial results and a corporate update for the quarter...
May 08, 2018 08:00 am ET
CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it began screening of patients for a phase 2b proof...
May 01, 2018 08:00 am ET
CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8
NEWARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference...
Apr 20, 2018 08:25 am ET
Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market — Future Expectations, Projec
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CymaBay Therapeutics Inc. (NASDAQ:CBAY), IAC/InterActiveCorp (NASDAQ:IAC),...
Apr 11, 2018 07:47 am ET
CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2018
NEWARK, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced that a late-breaking poster presentation describing new data from a second interim analysis of its ongoing Phase 2 study of seladelpar in patients with...
Mar 15, 2018 04:01 pm ET
Mar 06, 2018 08:00 am ET
CymaBay to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Thursday, March 15
NEWARK, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference...
Mar 05, 2018 08:00 am ET
CymaBay Therapeutics to Participate in Upcoming Investor Conferences in March
NEWARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.